Iranian Specialists Produce Nintedanib Drug for Pulmonary Fibrosis Patients
“The research, development and regulatory teams of Sana Pharmed company have succeeded in making this drug available to patients with global quality and standards, but at a price less than one-fifth of the foreign model, by utilizing modern production techniques,” said Maryam Navabakhsh, an expert at the medical department of Sana Pharmed pharmaceutical company.
“This drug is used to control all types of pulmonary fibrosis, including idiopathic pulmonary fibrosis (of unknown cause), caused by autoimmune diseases and other progressive types,” she added.
“Although it is not considered a definitive treatment, according to reliable scientific sources, it can increase the life expectancy of patients by an average of 9 to 11 years,” Navabakhsh said.
Nintedanib is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.
Common side effects include abdominal pain, vomiting, and diarrhea. It is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet derived growth factor receptor.
4155/v
